NCT00665743

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Naproxen 500 mg Administered as PN 400 (Naproxen / Esomeprazole), as the [Active Comparator 1], or as [Active Comparator 2] in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: POZEN · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations.

Conditions

• Arthritis

Interventions

Type	Name	Description
DRUG	PN400	naproxen 500 mg /esomeprazole 20 mg
DRUG	naproxen	naproxen 500 mg tablet
DRUG	naproxen	naproxen 500 mg

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2008-04-24
• Last updated: 2008-06-10

Locations

1 site across 1 country: United States